Live Attenuated Vaccine-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data
Report Summary
Live Attenuated Vaccine-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Live Attenuated Vaccine industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Live Attenuated Vaccine 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Live Attenuated Vaccine worldwide and market share by regions, with company and product introduction, position in the Live Attenuated Vaccine market
Market status and development trend of Live Attenuated Vaccine by types and applications
Cost and profit status of Live Attenuated Vaccine, and marketing status
Market growth drivers and challenges
The report segments the global Live Attenuated Vaccine market as:
Global Live Attenuated Vaccine Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Live Attenuated Vaccine Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Pediatrics
Adults
Global Live Attenuated Vaccine Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Medical Center
Others
Global Live Attenuated Vaccine Market: Manufacturers Segment Analysis (Company and Product introduction, Live Attenuated Vaccine Sales Volume, Revenue, Price and Gross Margin):
Astellas Pharma (Japan)
CSL Limited (Australia)
Emergent BioSolutions (U.S.)
GlaxoSmithKline (U.K.)
Johnson & Johnson (U.S.)
MedImmune (U.S.)
Merck & Co (U.S.)
Pfizer (U.S.)
Sanofi Pasteur (France)
Serum Institute of India Pvt (India)
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Live Attenuated Vaccine-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Live Attenuated Vaccine industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Live Attenuated Vaccine 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Live Attenuated Vaccine worldwide and market share by regions, with company and product introduction, position in the Live Attenuated Vaccine market
Market status and development trend of Live Attenuated Vaccine by types and applications
Cost and profit status of Live Attenuated Vaccine, and marketing status
Market growth drivers and challenges
The report segments the global Live Attenuated Vaccine market as:
Global Live Attenuated Vaccine Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Live Attenuated Vaccine Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Pediatrics
Adults
Global Live Attenuated Vaccine Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Medical Center
Others
Global Live Attenuated Vaccine Market: Manufacturers Segment Analysis (Company and Product introduction, Live Attenuated Vaccine Sales Volume, Revenue, Price and Gross Margin):
Astellas Pharma (Japan)
CSL Limited (Australia)
Emergent BioSolutions (U.S.)
GlaxoSmithKline (U.K.)
Johnson & Johnson (U.S.)
MedImmune (U.S.)
Merck & Co (U.S.)
Pfizer (U.S.)
Sanofi Pasteur (France)
Serum Institute of India Pvt (India)
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF LIVE ATTENUATED VACCINE
1.1 Definition of Live Attenuated Vaccine in This Report
1.2 Commercial Types of Live Attenuated Vaccine
1.2.1 Pediatrics
1.2.2 Adults
1.3 Downstream Application of Live Attenuated Vaccine
1.3.1 Hospital
1.3.2 Medical Center
1.3.3 Others
1.4 Development History of Live Attenuated Vaccine
1.5 Market Status and Trend of Live Attenuated Vaccine 2013-2023
1.5.1 Global Live Attenuated Vaccine Market Status and Trend 2013-2023
1.5.2 Regional Live Attenuated Vaccine Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Live Attenuated Vaccine 2013-2017
2.2 Sales Market of Live Attenuated Vaccine by Regions
2.2.1 Sales Volume of Live Attenuated Vaccine by Regions
2.2.2 Sales Value of Live Attenuated Vaccine by Regions
2.3 Production Market of Live Attenuated Vaccine by Regions
2.4 Global Market Forecast of Live Attenuated Vaccine 2018-2023
2.4.1 Global Market Forecast of Live Attenuated Vaccine 2018-2023
2.4.2 Market Forecast of Live Attenuated Vaccine by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Live Attenuated Vaccine by Types
3.2 Sales Value of Live Attenuated Vaccine by Types
3.3 Market Forecast of Live Attenuated Vaccine by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Live Attenuated Vaccine by Downstream Industry
4.2 Global Market Forecast of Live Attenuated Vaccine by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Live Attenuated Vaccine Market Status by Countries
5.1.1 North America Live Attenuated Vaccine Sales by Countries (2013-2017)
5.1.2 North America Live Attenuated Vaccine Revenue by Countries (2013-2017)
5.1.3 United States Live Attenuated Vaccine Market Status (2013-2017)
5.1.4 Canada Live Attenuated Vaccine Market Status (2013-2017)
5.1.5 Mexico Live Attenuated Vaccine Market Status (2013-2017)
5.2 North America Live Attenuated Vaccine Market Status by Manufacturers
5.3 North America Live Attenuated Vaccine Market Status by Type (2013-2017)
5.3.1 North America Live Attenuated Vaccine Sales by Type (2013-2017)
5.3.2 North America Live Attenuated Vaccine Revenue by Type (2013-2017)
5.4 North America Live Attenuated Vaccine Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Live Attenuated Vaccine Market Status by Countries
6.1.1 Europe Live Attenuated Vaccine Sales by Countries (2013-2017)
6.1.2 Europe Live Attenuated Vaccine Revenue by Countries (2013-2017)
6.1.3 Germany Live Attenuated Vaccine Market Status (2013-2017)
6.1.4 UK Live Attenuated Vaccine Market Status (2013-2017)
6.1.5 France Live Attenuated Vaccine Market Status (2013-2017)
6.1.6 Italy Live Attenuated Vaccine Market Status (2013-2017)
6.1.7 Russia Live Attenuated Vaccine Market Status (2013-2017)
6.1.8 Spain Live Attenuated Vaccine Market Status (2013-2017)
6.1.9 Benelux Live Attenuated Vaccine Market Status (2013-2017)
6.2 Europe Live Attenuated Vaccine Market Status by Manufacturers
6.3 Europe Live Attenuated Vaccine Market Status by Type (2013-2017)
6.3.1 Europe Live Attenuated Vaccine Sales by Type (2013-2017)
6.3.2 Europe Live Attenuated Vaccine Revenue by Type (2013-2017)
6.4 Europe Live Attenuated Vaccine Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Live Attenuated Vaccine Market Status by Countries
7.1.1 Asia Pacific Live Attenuated Vaccine Sales by Countries (2013-2017)
7.1.2 Asia Pacific Live Attenuated Vaccine Revenue by Countries (2013-2017)
7.1.3 China Live Attenuated Vaccine Market Status (2013-2017)
7.1.4 Japan Live Attenuated Vaccine Market Status (2013-2017)
7.1.5 India Live Attenuated Vaccine Market Status (2013-2017)
7.1.6 Southeast Asia Live Attenuated Vaccine Market Status (2013-2017)
7.1.7 Australia Live Attenuated Vaccine Market Status (2013-2017)
7.2 Asia Pacific Live Attenuated Vaccine Market Status by Manufacturers
7.3 Asia Pacific Live Attenuated Vaccine Market Status by Type (2013-2017)
7.3.1 Asia Pacific Live Attenuated Vaccine Sales by Type (2013-2017)
7.3.2 Asia Pacific Live Attenuated Vaccine Revenue by Type (2013-2017)
7.4 Asia Pacific Live Attenuated Vaccine Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Live Attenuated Vaccine Market Status by Countries
8.1.1 Latin America Live Attenuated Vaccine Sales by Countries (2013-2017)
8.1.2 Latin America Live Attenuated Vaccine Revenue by Countries (2013-2017)
8.1.3 Brazil Live Attenuated Vaccine Market Status (2013-2017)
8.1.4 Argentina Live Attenuated Vaccine Market Status (2013-2017)
8.1.5 Colombia Live Attenuated Vaccine Market Status (2013-2017)
8.2 Latin America Live Attenuated Vaccine Market Status by Manufacturers
8.3 Latin America Live Attenuated Vaccine Market Status by Type (2013-2017)
8.3.1 Latin America Live Attenuated Vaccine Sales by Type (2013-2017)
8.3.2 Latin America Live Attenuated Vaccine Revenue by Type (2013-2017)
8.4 Latin America Live Attenuated Vaccine Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Live Attenuated Vaccine Market Status by Countries
9.1.1 Middle East and Africa Live Attenuated Vaccine Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Live Attenuated Vaccine Revenue by Countries (2013-2017)
9.1.3 Middle East Live Attenuated Vaccine Market Status (2013-2017)
9.1.4 Africa Live Attenuated Vaccine Market Status (2013-2017)
9.2 Middle East and Africa Live Attenuated Vaccine Market Status by Manufacturers
9.3 Middle East and Africa Live Attenuated Vaccine Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Live Attenuated Vaccine Sales by Type (2013-2017)
9.3.2 Middle East and Africa Live Attenuated Vaccine Revenue by Type (2013-2017)
9.4 Middle East and Africa Live Attenuated Vaccine Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF LIVE ATTENUATED VACCINE
10.1 Global Economy Situation and Trend Overview
10.2 Live Attenuated Vaccine Downstream Industry Situation and Trend Overview
CHAPTER 11 LIVE ATTENUATED VACCINE MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Live Attenuated Vaccine by Major Manufacturers
11.2 Production Value of Live Attenuated Vaccine by Major Manufacturers
11.3 Basic Information of Live Attenuated Vaccine by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Live Attenuated Vaccine Major Manufacturer
11.3.2 Employees and Revenue Level of Live Attenuated Vaccine Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 LIVE ATTENUATED VACCINE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Astellas Pharma (Japan)
12.1.1 Company profile
12.1.2 Representative Live Attenuated Vaccine Product
12.1.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Astellas Pharma (Japan)
12.2 CSL Limited (Australia)
12.2.1 Company profile
12.2.2 Representative Live Attenuated Vaccine Product
12.2.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of CSL Limited (Australia)
12.3 Emergent BioSolutions (U.S.)
12.3.1 Company profile
12.3.2 Representative Live Attenuated Vaccine Product
12.3.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Emergent BioSolutions (U.S.)
12.4 GlaxoSmithKline (U.K.)
12.4.1 Company profile
12.4.2 Representative Live Attenuated Vaccine Product
12.4.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of GlaxoSmithKline (U.K.)
12.5 Johnson & Johnson (U.S.)
12.5.1 Company profile
12.5.2 Representative Live Attenuated Vaccine Product
12.5.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Johnson & Johnson (U.S.)
12.6 MedImmune (U.S.)
12.6.1 Company profile
12.6.2 Representative Live Attenuated Vaccine Product
12.6.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of MedImmune (U.S.)
12.7 Merck & Co (U.S.)
12.7.1 Company profile
12.7.2 Representative Live Attenuated Vaccine Product
12.7.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Merck & Co (U.S.)
12.8 Pfizer (U.S.)
12.8.1 Company profile
12.8.2 Representative Live Attenuated Vaccine Product
12.8.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Pfizer (U.S.)
12.9 Sanofi Pasteur (France)
12.9.1 Company profile
12.9.2 Representative Live Attenuated Vaccine Product
12.9.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Sanofi Pasteur (France)
12.10 Serum Institute of India Pvt (India)
12.10.1 Company profile
12.10.2 Representative Live Attenuated Vaccine Product
12.10.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Serum Institute of India Pvt (India)
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF LIVE ATTENUATED VACCINE
13.1 Industry Chain of Live Attenuated Vaccine
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF LIVE ATTENUATED VACCINE
14.1 Cost Structure Analysis of Live Attenuated Vaccine
14.2 Raw Materials Cost Analysis of Live Attenuated Vaccine
14.3 Labor Cost Analysis of Live Attenuated Vaccine
14.4 Manufacturing Expenses Analysis of Live Attenuated Vaccine
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Live Attenuated Vaccine in This Report
1.2 Commercial Types of Live Attenuated Vaccine
1.2.1 Pediatrics
1.2.2 Adults
1.3 Downstream Application of Live Attenuated Vaccine
1.3.1 Hospital
1.3.2 Medical Center
1.3.3 Others
1.4 Development History of Live Attenuated Vaccine
1.5 Market Status and Trend of Live Attenuated Vaccine 2013-2023
1.5.1 Global Live Attenuated Vaccine Market Status and Trend 2013-2023
1.5.2 Regional Live Attenuated Vaccine Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Live Attenuated Vaccine 2013-2017
2.2 Sales Market of Live Attenuated Vaccine by Regions
2.2.1 Sales Volume of Live Attenuated Vaccine by Regions
2.2.2 Sales Value of Live Attenuated Vaccine by Regions
2.3 Production Market of Live Attenuated Vaccine by Regions
2.4 Global Market Forecast of Live Attenuated Vaccine 2018-2023
2.4.1 Global Market Forecast of Live Attenuated Vaccine 2018-2023
2.4.2 Market Forecast of Live Attenuated Vaccine by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Live Attenuated Vaccine by Types
3.2 Sales Value of Live Attenuated Vaccine by Types
3.3 Market Forecast of Live Attenuated Vaccine by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Live Attenuated Vaccine by Downstream Industry
4.2 Global Market Forecast of Live Attenuated Vaccine by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Live Attenuated Vaccine Market Status by Countries
5.1.1 North America Live Attenuated Vaccine Sales by Countries (2013-2017)
5.1.2 North America Live Attenuated Vaccine Revenue by Countries (2013-2017)
5.1.3 United States Live Attenuated Vaccine Market Status (2013-2017)
5.1.4 Canada Live Attenuated Vaccine Market Status (2013-2017)
5.1.5 Mexico Live Attenuated Vaccine Market Status (2013-2017)
5.2 North America Live Attenuated Vaccine Market Status by Manufacturers
5.3 North America Live Attenuated Vaccine Market Status by Type (2013-2017)
5.3.1 North America Live Attenuated Vaccine Sales by Type (2013-2017)
5.3.2 North America Live Attenuated Vaccine Revenue by Type (2013-2017)
5.4 North America Live Attenuated Vaccine Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Live Attenuated Vaccine Market Status by Countries
6.1.1 Europe Live Attenuated Vaccine Sales by Countries (2013-2017)
6.1.2 Europe Live Attenuated Vaccine Revenue by Countries (2013-2017)
6.1.3 Germany Live Attenuated Vaccine Market Status (2013-2017)
6.1.4 UK Live Attenuated Vaccine Market Status (2013-2017)
6.1.5 France Live Attenuated Vaccine Market Status (2013-2017)
6.1.6 Italy Live Attenuated Vaccine Market Status (2013-2017)
6.1.7 Russia Live Attenuated Vaccine Market Status (2013-2017)
6.1.8 Spain Live Attenuated Vaccine Market Status (2013-2017)
6.1.9 Benelux Live Attenuated Vaccine Market Status (2013-2017)
6.2 Europe Live Attenuated Vaccine Market Status by Manufacturers
6.3 Europe Live Attenuated Vaccine Market Status by Type (2013-2017)
6.3.1 Europe Live Attenuated Vaccine Sales by Type (2013-2017)
6.3.2 Europe Live Attenuated Vaccine Revenue by Type (2013-2017)
6.4 Europe Live Attenuated Vaccine Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Live Attenuated Vaccine Market Status by Countries
7.1.1 Asia Pacific Live Attenuated Vaccine Sales by Countries (2013-2017)
7.1.2 Asia Pacific Live Attenuated Vaccine Revenue by Countries (2013-2017)
7.1.3 China Live Attenuated Vaccine Market Status (2013-2017)
7.1.4 Japan Live Attenuated Vaccine Market Status (2013-2017)
7.1.5 India Live Attenuated Vaccine Market Status (2013-2017)
7.1.6 Southeast Asia Live Attenuated Vaccine Market Status (2013-2017)
7.1.7 Australia Live Attenuated Vaccine Market Status (2013-2017)
7.2 Asia Pacific Live Attenuated Vaccine Market Status by Manufacturers
7.3 Asia Pacific Live Attenuated Vaccine Market Status by Type (2013-2017)
7.3.1 Asia Pacific Live Attenuated Vaccine Sales by Type (2013-2017)
7.3.2 Asia Pacific Live Attenuated Vaccine Revenue by Type (2013-2017)
7.4 Asia Pacific Live Attenuated Vaccine Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Live Attenuated Vaccine Market Status by Countries
8.1.1 Latin America Live Attenuated Vaccine Sales by Countries (2013-2017)
8.1.2 Latin America Live Attenuated Vaccine Revenue by Countries (2013-2017)
8.1.3 Brazil Live Attenuated Vaccine Market Status (2013-2017)
8.1.4 Argentina Live Attenuated Vaccine Market Status (2013-2017)
8.1.5 Colombia Live Attenuated Vaccine Market Status (2013-2017)
8.2 Latin America Live Attenuated Vaccine Market Status by Manufacturers
8.3 Latin America Live Attenuated Vaccine Market Status by Type (2013-2017)
8.3.1 Latin America Live Attenuated Vaccine Sales by Type (2013-2017)
8.3.2 Latin America Live Attenuated Vaccine Revenue by Type (2013-2017)
8.4 Latin America Live Attenuated Vaccine Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Live Attenuated Vaccine Market Status by Countries
9.1.1 Middle East and Africa Live Attenuated Vaccine Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Live Attenuated Vaccine Revenue by Countries (2013-2017)
9.1.3 Middle East Live Attenuated Vaccine Market Status (2013-2017)
9.1.4 Africa Live Attenuated Vaccine Market Status (2013-2017)
9.2 Middle East and Africa Live Attenuated Vaccine Market Status by Manufacturers
9.3 Middle East and Africa Live Attenuated Vaccine Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Live Attenuated Vaccine Sales by Type (2013-2017)
9.3.2 Middle East and Africa Live Attenuated Vaccine Revenue by Type (2013-2017)
9.4 Middle East and Africa Live Attenuated Vaccine Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF LIVE ATTENUATED VACCINE
10.1 Global Economy Situation and Trend Overview
10.2 Live Attenuated Vaccine Downstream Industry Situation and Trend Overview
CHAPTER 11 LIVE ATTENUATED VACCINE MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Live Attenuated Vaccine by Major Manufacturers
11.2 Production Value of Live Attenuated Vaccine by Major Manufacturers
11.3 Basic Information of Live Attenuated Vaccine by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Live Attenuated Vaccine Major Manufacturer
11.3.2 Employees and Revenue Level of Live Attenuated Vaccine Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 LIVE ATTENUATED VACCINE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Astellas Pharma (Japan)
12.1.1 Company profile
12.1.2 Representative Live Attenuated Vaccine Product
12.1.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Astellas Pharma (Japan)
12.2 CSL Limited (Australia)
12.2.1 Company profile
12.2.2 Representative Live Attenuated Vaccine Product
12.2.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of CSL Limited (Australia)
12.3 Emergent BioSolutions (U.S.)
12.3.1 Company profile
12.3.2 Representative Live Attenuated Vaccine Product
12.3.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Emergent BioSolutions (U.S.)
12.4 GlaxoSmithKline (U.K.)
12.4.1 Company profile
12.4.2 Representative Live Attenuated Vaccine Product
12.4.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of GlaxoSmithKline (U.K.)
12.5 Johnson & Johnson (U.S.)
12.5.1 Company profile
12.5.2 Representative Live Attenuated Vaccine Product
12.5.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Johnson & Johnson (U.S.)
12.6 MedImmune (U.S.)
12.6.1 Company profile
12.6.2 Representative Live Attenuated Vaccine Product
12.6.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of MedImmune (U.S.)
12.7 Merck & Co (U.S.)
12.7.1 Company profile
12.7.2 Representative Live Attenuated Vaccine Product
12.7.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Merck & Co (U.S.)
12.8 Pfizer (U.S.)
12.8.1 Company profile
12.8.2 Representative Live Attenuated Vaccine Product
12.8.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Pfizer (U.S.)
12.9 Sanofi Pasteur (France)
12.9.1 Company profile
12.9.2 Representative Live Attenuated Vaccine Product
12.9.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Sanofi Pasteur (France)
12.10 Serum Institute of India Pvt (India)
12.10.1 Company profile
12.10.2 Representative Live Attenuated Vaccine Product
12.10.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Serum Institute of India Pvt (India)
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF LIVE ATTENUATED VACCINE
13.1 Industry Chain of Live Attenuated Vaccine
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF LIVE ATTENUATED VACCINE
14.1 Cost Structure Analysis of Live Attenuated Vaccine
14.2 Raw Materials Cost Analysis of Live Attenuated Vaccine
14.3 Labor Cost Analysis of Live Attenuated Vaccine
14.4 Manufacturing Expenses Analysis of Live Attenuated Vaccine
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
